Gulf War Illness
Released: January 27, 2021
Defense Health Program
Department of Defense Gulf War Illness Research Program
Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)
The FY21 Defense Appropriations Act provides funding to the Department of Defense Gulf War Illness Research Program (GWIRP) to support research addressing Gulf War Illness treatment, diagnosis and pathobiology underlying symptoms of disease. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
The GWIRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY21 funding opportunities. This pre-announcement should not be construed as an obligation by the Government. The FY21 GWIRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released.
Applications submitted to the FY21 GWIRP must address one or more of the following overarching challenges:
- Treatments: Eliminate the health consequences associated with Gulf War Illness (GWI) and/or revolutionize treatment.
- Diagnosis: Better define and diagnose GWI.
- Subtyping: Distinguish subtypes to better target treatments; or monitor therapy; or identify severity of GWI; or why GWI is worse for some Veterans than for others.
- Determinants: Identify and validate determinants of GWI, latency, and impacts on organs and systems.
- Consequences: Determine whether GWI alters risk for developing neurological conditions, cancers, or other serious conditions; or whether GWI alters outcomes of other infections/diseases.
- Communicate & Educate: Help Veterans, their caregivers, and clinicians communicate effectively about GWI, its symptoms, and potential treatments.
|Award Mechanism||PI Eligibility||Key Mechanism Elements||Funding|
|Idea Award||Independent investigators at all academic levels.||
|Research Advancement Award||Independent investigators at all academic levels.||
|Clinical Evaluation Award||Independent investigators at all academic levels.||
|Therapeutic/Biomarker Trial Award||Independent investigators at all academic levels.||
|New Investigator Award||
Transitioning Postdoctoral Fellow: Senior postdoctoral fellows with at least 3 years of postdoctoral training.
Early-Career Investigator: Independent investigators within 5 years of last training position.
New GWI Researcher: Established independent investigators who have received less than $300,000 in federally funded, non-mentored GWI research.
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the GWIRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs
Last updated Thursday, May 26, 2022